Drug Target Review

DECEMBER 6, 2024

In drug discovery and biological research, the scientists workflow often follows a structured and iterative approach to ensure accuracy, reproducibility and scientific integrity. Figure 1: High-level workflow for early drug discovery Once the raw data has been gathered, the next step is to gain a thorough understanding of the data.

RNA 52

RNA Drugs Research Science 52

Chemical Biology and Drug Design

MARCH 28, 2023

In this study, 255 drug targets of metformin were obtained from the BATMAN, Drugbank, PharmMapper, SwissTargetPrediction, and TargetNet databases. A total of 95 common targets were obtained by deintersection of drug targets of metformin and DEGs in OC.

Bioinformatics 100

Bioinformatics Drugs Research 100

Drug Target Review

MARCH 28, 2024

Between 2000 and 2020, approximately 30 percent of the newly introduced small molecule drugs were derived from natural products. In recent decades there has been a decline in interest in natural products for drug discovery, with the industry gravitating towards screening libraries of synthetic molecules with predefined chemistries.

Production 128

Production Drugs Small Molecule Bioinformatics 128

Chemical Biology and Drug Design

JULY 4, 2023

Acacetin, as a natural flavonoid drug, modulates the activity of JAK2/STAT3 pathway, to suppress the growth, migration, invasion and anti-apoptosis of cancer cells and block the progression of esophageal cancer. Acacetin may be a promising drug in complementary therapy of cancer treatment.

Bioinformatics 100

Bioinformatics Regulations Treatment Therapies 100

Chemical Biology and Drug Design

JULY 13, 2023

Bioinformatics analysis was performed to predict the molecular targets of COP. In summary, COP represses the malignant biological behaviors of bladder carcinoma cells and regulates XPO1 expression, which is promising to be a complementary drug for bladder carcinoma treatment.

Regulations 100

Regulations Bioinformatics Treatment Drugs 100

The Open Targets Blog

OCTOBER 31, 2023

The National Cancer Institute (NCI)’s Childhood Cancer Data Initiative (CCDI) is supporting the development of an instance of the Open Targets Platform specific to childhood cancers for systematic drug target identification and prioritisation. Food and Drug Administration (FDA).

Bioinformatics 67

Bioinformatics Engineering Clinical Trials Therapies 67

Practical Cheminformatics

JANUARY 8, 2024

Picking up where we left off in Part I , this post covers several other ML in drug discovery topics that interested me in 2023. Most of the LLM activity in the drug discovery space in 2023 was reported as preprints from academic groups. Most of the drug discovery examples were underwhelming. Here’s the structure of Part II.

Drugs 139

Drugs Small Molecule Bioinformatics Packaging 139

ASPET

JANUARY 23, 2024

Most idiosyncratic drug reactions (IDRs) appear to be immune-mediated, but mechanistic events preceding severe reaction onset remain poorly defined. Moreover, treatment of drug-naïve THP-1 cells with clozapine-exposed EVs induced an inflammasome-dependent response, supporting a potential role for EVs in immune activation.

Immune Response 100

Immune Response Bioinformatics Regulations Drugs 100

Drug Target Review

DECEMBER 28, 2023

Recent advances in bioinformatics show clonal neoantigens are the best targets for immunotherapy, as I will elucidate below. Using powerful bioinformatics technology developed and validated with sequence data from the TRACERx study, researchers are able to identify clonal neoantigens from a patient’s unique tumour profile.

Bioinformatics 105

Bioinformatics Immune Response DNA Vaccine 105

Chemical Biology and Drug Design

NOVEMBER 27, 2023

The expression and activity of AchE is changed in tumors, suggesting AChE inhibitors (AchEIs) may serve as potential antitumor drugs. Moreover, bioinformatic analysis and cell viability test showed A6 plays anticancer role by regulating Best1 and HIST1H2BJ.

Bioinformatics 100

Bioinformatics RNA Regulations Therapies 100

Chemical Biology and Drug Design

DECEMBER 28, 2023

In present study, LINC00460 was screened out through bioinformatics analysis. Silencing of LINC00460 increased drug sensitivity and induced apoptosis in DDP-resistant-cervical cancer cells. The prognostic value of long noncoding RNA (lncRNA) LINC00460 has been reported in cervical cancer.

Bioinformatics 100

Bioinformatics RNA Regulations Drugs 100

Chemical Biology and Drug Design

JUNE 21, 2023

Hsa-miR-503-5p expression in LUAD and the target gene downstream of hsa-miR-503-5p was predicted by bioinformatics analysis. Abstract The study aimed to assess the role of hsa-miR-503-5p in cisplatin resistance and angiogenesis in LUAD and its underlying mechanisms. Hsa-miR-503-5p also had high expression in cisplatin-resistant LUAD cells.

Regulations 100

Regulations Protein Expression Bioinformatics Drugs 100

Chemical Biology and Drug Design

MARCH 14, 2023

EVO regulates ovarian cancer progression through the NEAT1-miR-152-3p-CDK19 axis, which further advances the possibility of EVO as a therapeutic drug for ovarian cancer. Abstract Evodiamine (EVO) has been demonstrated to promote apoptosis of ovarian cancer cells, and upregulate miR-152-3p level in colorectal cancer.

Regulations 100

Regulations Bioinformatics Drugs Research 100

Crown Bioscience

NOVEMBER 6, 2024

Mouse Clinical Trials (MCTs) are a cornerstone of preclinical oncology research, providing valuable insights into drug efficacy and biomarker discovery. However, the success of these trials hinges on precise study design, appropriate model selection, and rigorous data analysis.

Clinical Trials 52

Clinical Trials Bioinformatics Trials Research 52

Drug Target Review

JULY 12, 2023

These assays provide insights into the molecular mechanisms of disease biology and drug response, enabling the characterisation of gene expression profiles and deviations in diseased cells. This platform can help identify and optimise pharmacologic properties of new drugs.

Biochemical Assays 98

Biochemical Assays Treatment Bioinformatics Disease 98

Broad Institute

OCTOBER 27, 2023

Machine Learning in Drug Discovery Symposium 2023 | Opening Remarks By Rose Circeo October 27, 2023 Breadcrumb Home Machine Learning in Drug Discovery Symposium 2023 | Opening Remarks Sumaiya Iqbal Group Leader Bioinformatics and Computational Biology Group Center for the Development of Therapeutics Broad Institute Alex Burgin Senior Director Center (..)

Bioinformatics 52

Bioinformatics Drugs 52

Crown Bioscience

MARCH 12, 2025

The integration of artificial intelligence (AI) and bioinformatics into oncology research has revolutionized how we approach drug discovery, tumor modeling, and patient-specific therapy design.

Bioinformatics 52

Bioinformatics Therapies Research Drugs 52

Crown Bioscience

JANUARY 9, 2024

We have published our study on " SynAI " in the journal " Bioinformatics Advances " (November 2023). SynAI is an AI-driven platform designed to predict the synergistic effects of cancer drug combinations, poised to fundamentally change how we discover and evaluate cancer treatments.

Bioinformatics 52

Bioinformatics Drugs Treatment Research 52

Elrig

APRIL 29, 2024

Webinar | Ai At The Frontier: Empowering Early Career Professionals In Drug Discovery WEBINAR – ARE YOU CURIOUS ABOUT THE CUTTING-EDGE INTERSECTION OF ARTIFICIAL INTELLIGENCE AND DRUG DISCOVERY? Are you curious about the cutting-edge intersection of Artificial Intelligence and Drug Discovery?

Bioinformatics 59

Bioinformatics Drugs Molecular Biology Cell Based Assays 59

Crown Bioscience

OCTOBER 11, 2024

Mathematical Modeling of Tumor Growth Curves and Its Application in Biomarker Discovery for Anti-Tumor Drugs Breaking down the data from our recent research In last month’s issue of Cancer Research Communications, scientist Drs.

Bioinformatics 52

Bioinformatics Science Research Drugs 52

Broad Institute

MARCH 8, 2024

Organizing Committee By Rose Circeo March 8, 2024 Breadcrumb Home Organizing Committee Sumaiya Iqbal, Co-chair Group Leader, Bioinformatics and Computational Biology, CDoT Wengong Jin, Co-chair Postdoc, Eric and Wendy Schmidt Center Holly Soutter, General Committee Member Director, Biochemistry and Biophysics, CDoT Eric Sigel, General Committee Member (..)

Bioinformatics 52

Bioinformatics Science Research Drugs 52

Broad Institute

MARCH 8, 2024

Organizing Committee By Rose Circeo March 8, 2024 Breadcrumb Home Organizing Committee Sumaiya Iqbal, Co-chair Group Leader, Bioinformatics and Computational Biology, CDoT Wengong Jin, Co-chair Postdoc, Eric and Wendy Schmidt Center Holly Soutter, General Committee Member Director, Biochemistry and Biophysics, CDoT Eric Sigel, General Committee Member (..)

Bioinformatics 52

Bioinformatics Science Research Drugs 52

Drug Target Review

SEPTEMBER 26, 2024

Dr Mutlu Dogruel is the VP of AI Solutions, who has outlined a forward-thinking vision to revolutionise drug discovery processes by integrating cutting-edge AI technologies to enhance productivity, streamline workflows, and empower researchers. What are the potential benefits associated with using AI to generate new drug candidates?

Drugs 64

Drugs Production Research Small Molecule 64

Nvidia Developer: Drug Discovery

DECEMBER 19, 2023

Advances in these scientific challenges are a critical necessity to further advance drug discovery, environmental science, and bioengineering. Basecamp Research, along with other life sciences entities, is integrating its workflow with NVIDIA BioNeMo, a generative AI platform geared towards drug discovery.

Science 102

Science Small Molecule Bioinformatics Research 102

Drug Target Review

JULY 24, 2023

The first identification was based on a bioinformatic analysis. Apicoplast is performing essential functions in the parasite lifecycle and thus has been considered an important target of anti-malarial drugs. Other than essential cellular processes are likely occurring in the apicoplast compartment.

RNA 98

RNA Regulations Bioinformatics Laboratories 98

Drug Target Review

MARCH 19, 2024

This is also important considering that too much of the vitamin can also be harmful, particularly to the developing foetus and therefore supplements and retinoid drugs should only be given under medical supervision, especially in women of childbearing age. This study by Reay and colleagues was published in Nature Communications.

Laboratories 105

Laboratories Bioinformatics International Research Laboratories 105

DrugBank

FEBRUARY 12, 2025

The pharmaceutical industry grapples with the persistent challenge of high attrition rates and escalating costs inherent in drug development. This necessitates exploring alternative strategies to expedite drug discovery and optimize resource allocation.

Cell Based Assays 52

Cell Based Assays Drugs Pharmacokinetics Disease 52

The Premier Consulting Blog

JUNE 18, 2023

This has opened new opportunities in pharmaceutical drug development, such as the ability to evaluate large complex databases and to integrate information in useful ways. A similar draft guidance document for drug development is in process. 1 Among the topics highlighted is the “model-informed drug development (MIDD) initiative.”

Drug Development 52

Drug Development Disease Clinical Trials Drugs 52

DrugBank

JUNE 5, 2023

Chris Klinger, Scientific Support Lead, Bioinformatics LinkedIn It sounds like there was a lot going on at BioIT, what were your highlights? There were several excellent presentations on how to use AI/ML/data science to advance drug discovery efforts. Did you learn anything that surprised you?

Bioinformatics 98

Bioinformatics Clinical Trials Science Drugs 98

Fierce BioTech

OCTOBER 26, 2023

They turned to Oracle Cloud Infrastructure to quickly deploy, optimize, and scale a bioinformatics pipeline for predicting protein structures in drug discovery efforts, as well as accelerate the adoption of a next-generation archive storage technology.

DNA 52

DNA Bioinformatics Engineering Science 52

The Open Targets Blog

AUGUST 13, 2024

Building and Sustaining I have huge admiration for the incredible teams at EMBL’s European Bioinformatics Institute and beyond who build and sustain knowledge resources for the community. We also know there is lots more to do and I still think drug target decision making is a difficult problem.

Bioinformatics 70

Bioinformatics Disease Treatment Drugs 70

DrugBaron

NOVEMBER 22, 2022

As a commercial drug discovery company, much of their progress has been shielded from public gaze, even as they made ground-breaking advances to the technology platform. A wide range of proprietary bioinformatic tools are then used to extract knowledge from these ultra-large, ultra-accurate datasets.

Bioinformatics 100

Bioinformatics Regulations Molecular Biology Engineering 100

Drug Target Review

SEPTEMBER 30, 2024

Traditional drug discovery is based on the premise that target proteins have biological functions. Drugs should shut off, or antagonise, proteins with undesirable functions. This is why our drugs can have a better therapeutic index. Our approach is simple: one drug, one model. Our approach represents a paradigm shift.

Bioinformatics 64

Bioinformatics Clinical Trials Clinical Development Treatment 64

Drug Target Review

APRIL 5, 2024

Finally, comprehensive genetic knowledge also facilitates the use of powerful bioinformatic tools that strengthen the cell-line development process, especially for enhanced protein expression or monoclonality assessment.

Protein Production 96

Protein Production Protein Expression Bioinformatics Production 96

Drug Target Review

JANUARY 15, 2024

N17350’s mechanism of action delivers three unique attributes for a cancer drug. Given the unique attributes of skin cancers, head and neck cancer, and triple-negative breast cancer, how does N17350’s mechanism offer advantages over conventional treatment approaches tailored to these specific cancers?

Treatment 105

Treatment Immune Response Therapies Clinical Trials 105

Drug Target Review

MAY 27, 2024

How does the company see antibody-drug conjugates (ADCs) fitting into this approach? Antibody-drug conjugates have seen explosive growth in the last few years which has materialised with numerous clinical trials demonstrating meaningful improvements in survival.

Clinical Trials 59

Clinical Trials Science Molecular Biology Bioinformatics 59

Drug Target Review

MAY 24, 2024

In principle, LLMs can change the world of drug discovery (as they are often claiming to do), but biology and chemistry are full of nuances and the expectations for how LLMs will actually impact drug discovery need to be kept reasonably low for the moment. Another big field of advancement is protein modelling and simulation.

RNA 59

RNA DNA Bioinformatics Science 59